Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P24386
UPID:
RAE1_HUMAN
Alternative names:
Choroideremia protein; Rab escort protein 1; TCD protein
Alternative UPACC:
P24386; A1L4D2; O43732
Background:
Rab proteins geranylgeranyltransferase component A 1, also known as Rab escort protein 1, plays a crucial role in the post-translational modification of Rab proteins. It is essential for their proper function in intracellular trafficking. The protein binds to unprenylated Rab proteins, facilitating their geranylgeranylation, a modification critical for their membrane attachment and biological activity.
Therapeutic significance:
The protein's link to Choroideremia, a degenerative eye disease leading to blindness, underscores its therapeutic significance. Understanding the role of Rab proteins geranylgeranyltransferase component A 1 could open doors to potential therapeutic strategies for treating Choroideremia and possibly other related disorders.